Therapix Biosciences

Givatayim, Israel Founded: 2014 • Age: 12 yrs Listed Acquired By FSD Pharma
Cannabinoid-based therapies for central nervous system disorders are developed.

About Therapix Biosciences

Therapix Biosciences is a Healthcare company based in Givatayim (Israel) founded in 2014, and was acquired by FSD Pharma in October 2018. Cannabinoid-based therapies for central nervous system disorders are developed. Its chief executive, as recorded, is Amitay Weiss. Its focus areas include Life Sciences, Pain Management, Drugs and Neuropathic Pain.

Company details

Therapix Biosciences was founded in 2014 in Givatayim, Israel, within the biotechnology sector. Operations center on drug development for central nervous system disorders, utilizing an intellectual property portfolio of cannabinoid drugs and novel delivery systems. The pipeline features two programs: Brain Bright, a synthetic cannabinoid therapy for brain-related conditions, and a treatment for Tourette Syndrome based on the entourage effect, which has received orphan drug designation.

  • Headquarters Givatayim, Israel
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website therapixbio.com
  • Social LinkedIn X Facebook
  • Acquired by FSD Pharma (Oct 2018)
Key Metrics

Funding Insights of Therapix Biosciences

  • Total Rounds 3
  • Last Round Post-IPO β€” $8.15M
  • First Round $2.25M

    (Apr 2019)

All 3 funding rounds of Therapix Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2021$8.15MPost-IPO––
–
Jun 2020$2.6MPost-IPO––
–
Apr 2019$2.25MPost-IPO––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Therapix Biosciences

Therapix Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include FSD Pharma.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Cannabis company engaged in cultivation, processing, and manufacturing related activities
2018fsdpharma.comCobourg, Canada
Premium access

Investor details for Therapix Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Therapix Biosciences

4 people are tracked at Therapix Biosciences (4 in leadership).

NameRoleGroup
Amitay Weiss
CEOLeadership
Gilad Bar-lev
CEO & Board MemberLeadership
Adi Zuloff-Shani
Chief Technology OfficerLeadership
Oz Adler
CFOLeadership
Premium access

Complete people profiles for Therapix Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Therapix Biosciences

5 dated milestones of Therapix Biosciences across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Therapix Biosciences is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Exit Acquired by FSD Pharma.
  4. Funding First funding round of $2.2M.
  5. Funding Latest funding round, Post-IPO, of $8.2M.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Therapix Biosciences

Premium access

Complete news archive for Therapix Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Therapix Biosciences

Therapix Biosciences was founded in 2014 and raised its 1st funding round 5 years after it was founded.

Therapix Biosciences is headquartered in Givatayim, Israel. It is registered at Givatayim, Tel Aviv District, Israel.

Amitay Weiss is the CEO of Therapix Biosciences, as recorded in our data.

Therapix Biosciences was founded in 2014 in Givatayim, Israel, within the biotechnology sector. Operations center on drug development for central nervous system disorders, utilizing an intellectual property portfolio of cannabinoid drugs and novel delivery systems. The pipeline features two programs: Brain Bright, a synthetic cannabinoid therapy for brain-related conditions, and a treatment for Tourette Syndrome based on the entourage effect, which has received orphan drug designation.

Therapix Biosciences has 1 investor. Key investors include FSD Pharma.

Yes. Therapix Biosciences was acquired by FSD Pharma in October 2018.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available